STK-012

PreclinicalSmall molecule

SSynthekine

STK-012 is one of 59 small molecule programs targeting Lung Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Solid TumorRecruiting

Lung CancerPhase 1/Phase 2

Active, not recruiting

Solid TumorPreclinical

Recruiting

Competition

Competitive Landscape

686 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

9 2

Vizimpro

Pfizer

Preclinical

3 3

Libtayo

Regeneron

Preclinical

3 4

Talzenna

Pfizer

Preclinical

2 5

Folvite

Immunotherapy

5 7

Acupan

YYonsei University

Preclinical

—8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

COVID-19 Vaccine

1 10

Nicotine Replacement

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

PreclinicalRecruiting

Solid Tumor

NCT05098132

Clinical

Trials by Indication[1]

Solid Tumor1 trial

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications

Recruiting·SSynthekine·Preclinical·NCT05098132·364 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for STK-012. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — STK-012 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for STK-012. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Synthekine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSynthekine

STK-012

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News